| abstract |
The present invention provides an immunomodulatory agent useful for the treatment or prevention of joint damage, especially joint damage including joint damage in early RA (rheumatoid arthritis) or early RA patients. SOLUTION: (1) an inhibitor of NF-κB pathway, and an antigenic molecule selected from an antigen corresponding to all or part of an aggrecan polypeptide or a nucleic acid molecule capable of expressing the antigen; (2) mTOR inhibitor, And an antigenic molecule selected from an antigen corresponding to all or part of an aggrecan polypeptide or a nucleic acid molecule capable of expressing the antigen; (3) an inhibitor of the Syk pathway, and corresponding to all or part of an aggrecan polypeptide An agent comprising an antigen or an antigenic molecule selected from nucleic acid molecules capable of expressing the antigen; (4) a nucleic acid molecule encoding an antigen corresponding to all or part of an aggrecan polypeptide and introduced into B lymphocytes, etc. Composition. 【Selection chart】 None |